Cargando…

Exploring challenges in the management and treatment of inclusion body myositis

PURPOSE OF REVIEW: This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions. RECENT FINDINGS: IBM is a slowly progressive myopathy that predominantly affects patients over the age of 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skolka, Michael P., Naddaf, Elie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	MYOSITIS AND MYOPATHIES: Edited by Andrea Doria, Anna Ghirardello and Mariele Gatto
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552844/ https://www.ncbi.nlm.nih.gov/pubmed/37503813 http://dx.doi.org/10.1097/BOR.0000000000000958

Ejemplares similares

Update on muscle imaging in myositis
por: Tan, Ai Lyn, et al.
Publicado: (2023)

Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis
por: Rothwell, Simon, et al.
Publicado: (2019)

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies
por: Choi, May Y., et al.
Publicado: (2023)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

Immune‐Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum
por: Rothwell, Simon, et al.
Publicado: (2017)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Muscle Weakness in Myositis: MicroRNA‐Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies
por: Kinder, Travis B., et al.
Publicado: (2020)

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
por: Rothwell, Simon, et al.
Publicado: (2019)

Aberrant Muscle Antigen Exposure in Mice Is Sufficient to Cause Myositis in a Treg Cell–Deficient Milieu
por: Young, Nicholas A, et al.
Publicado: (2013)

Update in juvenile myositis
por: Nistala, Kiran, et al.
Publicado: (2013)

Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
por: Zhou, Danlei, et al.
Publicado: (2023)

Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry‐Based Study
por: Espinosa‐Ortega, Fabricio, et al.
Publicado: (2022)

Novel myosin-based therapies for congenital cardiac and skeletal myopathies
por: Ochala, Julien, et al.
Publicado: (2016)

Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments
por: Kawahata, Kimito, et al.
Publicado: (2023)

Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
por: Che, Weng Ian, et al.
Publicado: (2021)

Immunoproteasome subunit β5i promotes perifascicular muscle atrophy in dermatomyositis by upregulating RIG-I
por: Zhang, Lu, et al.
Publicado: (2023)

Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease
por: Chen, Xixia, et al.
Publicado: (2023)

Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023)

Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis
por: Oto, Yohsuke, et al.
Publicado: (2023)

Severe case of rhabdomyolysis following jellyfish envenomation in the Mediterranean Sea
por: Buscetta, Giorgio, et al.
Publicado: (2023)

In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study
por: Pijnenburg, Luc, et al.
Publicado: (2023)

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Inclusion body myositis: Update on the diagnostic and therapeutic landscape
por: Naddaf, Elie
Publicado: (2022)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Management of Cancer-Associated Myositis
por: Selva-O’Callaghan, Albert, et al.
Publicado: (2022)

Current Treatment for Myositis
por: Barsotti, Simone, et al.
Publicado: (2018)

Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges
por: Mohannak, Nika, et al.
Publicado: (2019)

Exercise in Myositis
por: Alexanderson, Helene
Publicado: (2018)

Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies
por: Qin, Li, et al.
Publicado: (2021)

Idiopathic inflammatory myopathies and hypertension: Possible involvement of hormonal factors
por: Armanini, Decio, et al.
Publicado: (2021)

New role of ventricular assist devices as bridge to transplantation: European perspective
por: Reineke, David C., et al.
Publicado: (2017)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Anesthetic management of a hydrocephalus patient with inclusion body myositis
por: Takekawa, Daiki, et al.
Publicado: (2017)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_eu2gcdf1k838uhpqhv22ilitdq